Literature DB >> 1480768

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy.

J C Horiot1, R Le Fur, T N'Guyen, C Chenal, S Schraub, S Alfonsi, G Gardani, W Van Den Bogaert, S Danczak, M Bolla.   

Abstract

EORTC protocol 22791 compared once daily fractionation (CF) of 70 Gy in 35-40 fractions in 7-8 weeks, to pure hyperfractionation (HF) of 80.5 Gy in 70 fractions in 7 weeks using 2 fractions of 1.15 Gy per day, in T2-T3 oropharyngeal carcinoma (excluding base of tongue), N0,N1 of less than 3 cm. From 1980 to 1987, 356 patients were entered. In the final analysis (June 1990), the local control was significantly higher (p = 0.02 log-rank) after HF compared with CF. At 5 years, 59% of patients are local disease-free in the HF arm compared to 40% in the CF arm. The superiority of HF was demonstrated in patients staged T3N0,T3N1 but not in T2. The Cox model confirmed that the treatment regimen was an independent significant prognostic factor for locoregional control (p = 0.007 log-rank). This improvement of locoregional control was responsible for a trend to an improved survival (p = 0.08 log-rank). There was no difference in late normal tissue damage between the two treatment modalities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480768     DOI: 10.1016/0167-8140(92)90242-m

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  63 in total

Review 1.  Altered fractionation in the treatment of head and neck cancer.

Authors:  K S Hu; L B Harrison
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

2.  Improving cancer outcomes through radiotherapy. Lack of UK radiotherapy resources prejudices cancer outcomes.

Authors:  N G Burnet; R J Benson; M V Williams; J H Peacock
Journal:  BMJ       Date:  2000-01-22

Review 3.  The impact on oncology of the interaction of radiation therapy and radiobiology.

Authors:  Vicente Pedraza Muriel
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

4.  Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.

Authors:  J Cvek; J Kubes; E Skacelikova; B Otahal; P Kominek; M Halamka; D Feltl
Journal:  Strahlenther Onkol       Date:  2012-06-01       Impact factor: 3.621

5.  Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.

Authors:  Valentina Krstevska; Simonida Crvenkova
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

6.  Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.

Authors:  F Arias; G Asín; M I Uzcanga; E Maraví; I Quílez; V Chicata; C Eito; A Viudez; I Hernández; F Mañeru; M A Domínguez
Journal:  Clin Transl Oncol       Date:  2013-11-08       Impact factor: 3.405

Review 7.  Linear quadratic and tumour control probability modelling in external beam radiotherapy.

Authors:  S F C O'Rourke; H McAneney; T Hillen
Journal:  J Math Biol       Date:  2008-09-30       Impact factor: 2.259

8.  [Reasons for the terms "radiosurgery" and "Gamma Knife"].

Authors:  K Hamm; G Surber
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

9.  Definitive Intensity-modulated Radiation Therapy in Elderly Patients with Locally Advanced Oropharyngeal Cancer.

Authors:  Francesca DE Felice; Alessandro Galdieri; Gessica Abate; Nadia Bulzonetti; Daniela Musio; Vincenzo Tombolini
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

10.  Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

Authors:  P Pedicini; R Caivano; A Fiorentino; L Strigari
Journal:  Clin Transl Oncol       Date:  2014-12-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.